Analyst consensus rating
Rein Therapeutics Analyst Rating: Strong Buy
RNTX is rated Strong Buy by 2 analysts with a $6.00 target. As of 2026-08-31.
Direct answer
Rein Therapeutics's consensus rating is Strong Buy.
2 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $6.00.
Forecast evidence checked August 31, 2026.
Get free Rein Therapeutics email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Current price
- $0.75
- Average price target
- $6.00
- High price target
- $8.00
- Low price target
- $4.00
- Low target gap
- +432.1%
- Target upside
- +698.2%
- High target gap
- +964.3%
- Target range width
- 532.1%
- Consensus rating
- Strong Buy
- Analysts
- 2
- Evidence date
- August 31, 2026
- Valid through
- September 7, 2026
Explore related company data
Read the frequently asked questions.
What is the analyst consensus rating for Rein Therapeutics?
Rein Therapeutics has a verified Strong Buy consensus. The same dataset has an average price target of $6.00.
How far are Rein Therapeutics's low and high targets from the recorded price?
The low target implies +432.1%, while the high target implies +964.3%.
How many analysts are included in Rein Therapeutics's consensus?
The verified consensus includes 2 analysts.
How is Rein Therapeutics's target upside or downside calculated?
The average target of $6.00 is divided by the recorded price of $0.75, then one is subtracted to produce +698.2%. This does not guarantee a future return.
When was Rein Therapeutics's analyst forecast verified?
The data was verified on 2026-08-31. The dataset is valid through 2026-09-07.